EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer

Michael K. Sanders, Arthur J. Moser, Asif Khalid, Kenneth E. Fasanella, Herbert J. Zeh, Steven Burton, Kevin McGrath

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background: Stereotactic body radiotherapy (SBRT) has been approved for the treatment of locally advanced pancreatic cancer. Placement of gold fiducials is required for real-time tracking and delivery of a high-dose therapeutic beam of radiation to the tumor. Traditionally, fiducials have been placed either intraoperatively or percutaneously. Recently, EUS-guided fiducial placement has been reported, but the safety and feasibility of this approach is not well defined. Objective: The aim of this study was to determine the safety, feasibility, and limitations of EUS-guided placement of 0.8 × 5.0 mm fiducials via a 19-gauge needle for locally advanced and recurrent pancreatic cancer. Design: Prospective study of patients with either locally advanced or recurrent pancreatic cancer referred for EUS-guided fiducial placement for SBRT at our institution over a 3-year period. Setting: Tertiary referral center conducting >1800 EUS procedures annually. Main Outcome Measurements: Primary outcome measurements included success, complications, and technical limitations of EUS-guided fiducial placement in pancreatic cancer. In addition, the percentage of patients successfully completing SBRT after EUS-guided fiducial placement was determined. Results: A total of 51 patients (mean age 73 years; 57% male) with locally advanced (n = 36) and recurrent (n = 15) pancreatic cancer were referred for EUS-guided fiducial placement. Fiducials were successfully placed in 46 patients (90%), with technical failures occurring in 4 patients (8%) with recurrent cancer after pancreaticoduodenectomy. In 3 patients (7%), the fiducials spontaneously migrated from the original site of injection, thereby requiring a second EUS procedure for placement of additional fiducials. Of the 46 patients with fiducials placed under EUS guidance, 42 patients (91%) successfully completed SBRT. Two patients experienced disease progression before SBRT, 1 patient was lost to follow-up, and 1 patient experienced a complication at ERCP that precluded further therapy. Only 1 complication (2%), of mild pancreatitis, occurred in a patient undergoing simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain. Limitations: Single-center experience and lack of a formal follow-up protocol to assess for complications. Conclusion: EUS-guided fiducial placement for SBRT in locally advanced and recurrent pancreatic cancer is safe and feasible. Successful placement was achieved in 90% of patients, with a low complication rate (2%). Furthermore, 91% of patients successfully completed SBRT after EUS-guided fiducial delivery. Although fiducials can spontaneously migrate from the initial injection site, the rate of migration is relatively low (7%), and no migration-related complications occurred over the course of this study. Limitations to EUS-guided fiducial placement may include surgically altered anatomy (pancreaticoduodenectomy) in patients with recurrent pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)1178-1184
Number of pages7
JournalGastrointestinal Endoscopy
Volume71
Issue number7
DOIs
StatePublished - Jun 2010
Externally publishedYes

Fingerprint

Radiosurgery
Pancreatic Neoplasms
Pancreaticoduodenectomy
Celiac Plexus
Safety
Intractable Pain
Injections
Endoscopic Retrograde Cholangiopancreatography
Lost to Follow-Up
Tertiary Care Centers
Gold
Pancreatitis
Abdominal Pain
Needles
Disease Progression

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Cite this

EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. / Sanders, Michael K.; Moser, Arthur J.; Khalid, Asif; Fasanella, Kenneth E.; Zeh, Herbert J.; Burton, Steven; McGrath, Kevin.

In: Gastrointestinal Endoscopy, Vol. 71, No. 7, 06.2010, p. 1178-1184.

Research output: Contribution to journalArticle

Sanders, Michael K. ; Moser, Arthur J. ; Khalid, Asif ; Fasanella, Kenneth E. ; Zeh, Herbert J. ; Burton, Steven ; McGrath, Kevin. / EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. In: Gastrointestinal Endoscopy. 2010 ; Vol. 71, No. 7. pp. 1178-1184.
@article{7d099da2ccd84672bd4d2b71ac83b3dc,
title = "EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer",
abstract = "Background: Stereotactic body radiotherapy (SBRT) has been approved for the treatment of locally advanced pancreatic cancer. Placement of gold fiducials is required for real-time tracking and delivery of a high-dose therapeutic beam of radiation to the tumor. Traditionally, fiducials have been placed either intraoperatively or percutaneously. Recently, EUS-guided fiducial placement has been reported, but the safety and feasibility of this approach is not well defined. Objective: The aim of this study was to determine the safety, feasibility, and limitations of EUS-guided placement of 0.8 × 5.0 mm fiducials via a 19-gauge needle for locally advanced and recurrent pancreatic cancer. Design: Prospective study of patients with either locally advanced or recurrent pancreatic cancer referred for EUS-guided fiducial placement for SBRT at our institution over a 3-year period. Setting: Tertiary referral center conducting >1800 EUS procedures annually. Main Outcome Measurements: Primary outcome measurements included success, complications, and technical limitations of EUS-guided fiducial placement in pancreatic cancer. In addition, the percentage of patients successfully completing SBRT after EUS-guided fiducial placement was determined. Results: A total of 51 patients (mean age 73 years; 57{\%} male) with locally advanced (n = 36) and recurrent (n = 15) pancreatic cancer were referred for EUS-guided fiducial placement. Fiducials were successfully placed in 46 patients (90{\%}), with technical failures occurring in 4 patients (8{\%}) with recurrent cancer after pancreaticoduodenectomy. In 3 patients (7{\%}), the fiducials spontaneously migrated from the original site of injection, thereby requiring a second EUS procedure for placement of additional fiducials. Of the 46 patients with fiducials placed under EUS guidance, 42 patients (91{\%}) successfully completed SBRT. Two patients experienced disease progression before SBRT, 1 patient was lost to follow-up, and 1 patient experienced a complication at ERCP that precluded further therapy. Only 1 complication (2{\%}), of mild pancreatitis, occurred in a patient undergoing simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain. Limitations: Single-center experience and lack of a formal follow-up protocol to assess for complications. Conclusion: EUS-guided fiducial placement for SBRT in locally advanced and recurrent pancreatic cancer is safe and feasible. Successful placement was achieved in 90{\%} of patients, with a low complication rate (2{\%}). Furthermore, 91{\%} of patients successfully completed SBRT after EUS-guided fiducial delivery. Although fiducials can spontaneously migrate from the initial injection site, the rate of migration is relatively low (7{\%}), and no migration-related complications occurred over the course of this study. Limitations to EUS-guided fiducial placement may include surgically altered anatomy (pancreaticoduodenectomy) in patients with recurrent pancreatic cancer.",
author = "Sanders, {Michael K.} and Moser, {Arthur J.} and Asif Khalid and Fasanella, {Kenneth E.} and Zeh, {Herbert J.} and Steven Burton and Kevin McGrath",
year = "2010",
month = "6",
doi = "10.1016/j.gie.2009.12.020",
language = "English (US)",
volume = "71",
pages = "1178--1184",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer

AU - Sanders, Michael K.

AU - Moser, Arthur J.

AU - Khalid, Asif

AU - Fasanella, Kenneth E.

AU - Zeh, Herbert J.

AU - Burton, Steven

AU - McGrath, Kevin

PY - 2010/6

Y1 - 2010/6

N2 - Background: Stereotactic body radiotherapy (SBRT) has been approved for the treatment of locally advanced pancreatic cancer. Placement of gold fiducials is required for real-time tracking and delivery of a high-dose therapeutic beam of radiation to the tumor. Traditionally, fiducials have been placed either intraoperatively or percutaneously. Recently, EUS-guided fiducial placement has been reported, but the safety and feasibility of this approach is not well defined. Objective: The aim of this study was to determine the safety, feasibility, and limitations of EUS-guided placement of 0.8 × 5.0 mm fiducials via a 19-gauge needle for locally advanced and recurrent pancreatic cancer. Design: Prospective study of patients with either locally advanced or recurrent pancreatic cancer referred for EUS-guided fiducial placement for SBRT at our institution over a 3-year period. Setting: Tertiary referral center conducting >1800 EUS procedures annually. Main Outcome Measurements: Primary outcome measurements included success, complications, and technical limitations of EUS-guided fiducial placement in pancreatic cancer. In addition, the percentage of patients successfully completing SBRT after EUS-guided fiducial placement was determined. Results: A total of 51 patients (mean age 73 years; 57% male) with locally advanced (n = 36) and recurrent (n = 15) pancreatic cancer were referred for EUS-guided fiducial placement. Fiducials were successfully placed in 46 patients (90%), with technical failures occurring in 4 patients (8%) with recurrent cancer after pancreaticoduodenectomy. In 3 patients (7%), the fiducials spontaneously migrated from the original site of injection, thereby requiring a second EUS procedure for placement of additional fiducials. Of the 46 patients with fiducials placed under EUS guidance, 42 patients (91%) successfully completed SBRT. Two patients experienced disease progression before SBRT, 1 patient was lost to follow-up, and 1 patient experienced a complication at ERCP that precluded further therapy. Only 1 complication (2%), of mild pancreatitis, occurred in a patient undergoing simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain. Limitations: Single-center experience and lack of a formal follow-up protocol to assess for complications. Conclusion: EUS-guided fiducial placement for SBRT in locally advanced and recurrent pancreatic cancer is safe and feasible. Successful placement was achieved in 90% of patients, with a low complication rate (2%). Furthermore, 91% of patients successfully completed SBRT after EUS-guided fiducial delivery. Although fiducials can spontaneously migrate from the initial injection site, the rate of migration is relatively low (7%), and no migration-related complications occurred over the course of this study. Limitations to EUS-guided fiducial placement may include surgically altered anatomy (pancreaticoduodenectomy) in patients with recurrent pancreatic cancer.

AB - Background: Stereotactic body radiotherapy (SBRT) has been approved for the treatment of locally advanced pancreatic cancer. Placement of gold fiducials is required for real-time tracking and delivery of a high-dose therapeutic beam of radiation to the tumor. Traditionally, fiducials have been placed either intraoperatively or percutaneously. Recently, EUS-guided fiducial placement has been reported, but the safety and feasibility of this approach is not well defined. Objective: The aim of this study was to determine the safety, feasibility, and limitations of EUS-guided placement of 0.8 × 5.0 mm fiducials via a 19-gauge needle for locally advanced and recurrent pancreatic cancer. Design: Prospective study of patients with either locally advanced or recurrent pancreatic cancer referred for EUS-guided fiducial placement for SBRT at our institution over a 3-year period. Setting: Tertiary referral center conducting >1800 EUS procedures annually. Main Outcome Measurements: Primary outcome measurements included success, complications, and technical limitations of EUS-guided fiducial placement in pancreatic cancer. In addition, the percentage of patients successfully completing SBRT after EUS-guided fiducial placement was determined. Results: A total of 51 patients (mean age 73 years; 57% male) with locally advanced (n = 36) and recurrent (n = 15) pancreatic cancer were referred for EUS-guided fiducial placement. Fiducials were successfully placed in 46 patients (90%), with technical failures occurring in 4 patients (8%) with recurrent cancer after pancreaticoduodenectomy. In 3 patients (7%), the fiducials spontaneously migrated from the original site of injection, thereby requiring a second EUS procedure for placement of additional fiducials. Of the 46 patients with fiducials placed under EUS guidance, 42 patients (91%) successfully completed SBRT. Two patients experienced disease progression before SBRT, 1 patient was lost to follow-up, and 1 patient experienced a complication at ERCP that precluded further therapy. Only 1 complication (2%), of mild pancreatitis, occurred in a patient undergoing simultaneous placement of fiducials and celiac plexus neurolysis for intractable abdominal pain. Limitations: Single-center experience and lack of a formal follow-up protocol to assess for complications. Conclusion: EUS-guided fiducial placement for SBRT in locally advanced and recurrent pancreatic cancer is safe and feasible. Successful placement was achieved in 90% of patients, with a low complication rate (2%). Furthermore, 91% of patients successfully completed SBRT after EUS-guided fiducial delivery. Although fiducials can spontaneously migrate from the initial injection site, the rate of migration is relatively low (7%), and no migration-related complications occurred over the course of this study. Limitations to EUS-guided fiducial placement may include surgically altered anatomy (pancreaticoduodenectomy) in patients with recurrent pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=77952874646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952874646&partnerID=8YFLogxK

U2 - 10.1016/j.gie.2009.12.020

DO - 10.1016/j.gie.2009.12.020

M3 - Article

C2 - 20362284

AN - SCOPUS:77952874646

VL - 71

SP - 1178

EP - 1184

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 7

ER -